ATE454153T1 - 5-ht4 antagonisten zur behandlung von herzversagen - Google Patents

5-ht4 antagonisten zur behandlung von herzversagen

Info

Publication number
ATE454153T1
ATE454153T1 AT03725415T AT03725415T ATE454153T1 AT E454153 T1 ATE454153 T1 AT E454153T1 AT 03725415 T AT03725415 T AT 03725415T AT 03725415 T AT03725415 T AT 03725415T AT E454153 T1 ATE454153 T1 AT E454153T1
Authority
AT
Austria
Prior art keywords
heart failure
antagonists
treatment
heart
treating
Prior art date
Application number
AT03725415T
Other languages
English (en)
Inventor
Finn Levy
Original Assignee
Serodus As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serodus As filed Critical Serodus As
Application granted granted Critical
Publication of ATE454153T1 publication Critical patent/ATE454153T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Treatment Of Sludge (AREA)
  • Electrotherapy Devices (AREA)
AT03725415T 2002-05-16 2003-05-16 5-ht4 antagonisten zur behandlung von herzversagen ATE454153T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0211230.8A GB0211230D0 (en) 2002-05-16 2002-05-16 Treatment of heart failure
PCT/GB2003/002134 WO2003097065A1 (en) 2002-05-16 2003-05-16 5-ht4 receptor antagonists for the treatment of heart failure

Publications (1)

Publication Number Publication Date
ATE454153T1 true ATE454153T1 (de) 2010-01-15

Family

ID=9936797

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03725415T ATE454153T1 (de) 2002-05-16 2003-05-16 5-ht4 antagonisten zur behandlung von herzversagen

Country Status (10)

Country Link
US (2) US20060094715A1 (de)
EP (1) EP1503764B1 (de)
AT (1) ATE454153T1 (de)
AU (2) AU2003227949B2 (de)
CA (1) CA2485600C (de)
DE (1) DE60330857D1 (de)
DK (1) DK1503764T3 (de)
ES (1) ES2339234T3 (de)
GB (1) GB0211230D0 (de)
WO (1) WO2003097065A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6278472B2 (ja) 2013-02-27 2018-02-14 塩野義製薬株式会社 Ａｍｐｋ活性化作用を有するインドールおよびアザインドール誘導体
US9956166B2 (en) 2013-09-18 2018-05-01 Sorrento Therapeutics, Inc. Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
EP3113777A4 (de) * 2014-03-04 2017-09-06 The Children's Hospital of Philadelphia Verfahren zum management der behandlung von patienten mit prädisposition für progressive mitralklappenerkrankungen
IL298314B2 (en) * 2016-04-13 2025-04-01 Univ Nebraska Methods of administration and methods of treating cardiovascular diseases with resiniparatoxin
CN115487175B (zh) * 2019-09-20 2024-05-14 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0018002B1 (de) 1979-04-24 1983-02-09 Marcel Jozefonvicz Neues Bestimmungsverfahren für Proteasen und Antiproteasen
US4888353A (en) 1986-02-28 1989-12-19 Erbamont, Inc. Carboxamides useful as antiemetic or antipsychotic agents
EP0201165B1 (de) 1985-03-14 1994-07-20 Beecham Group Plc Arzneimittel zur Behandlung von Emesis
US4851423A (en) 1986-12-10 1989-07-25 Schering Corporation Pharmaceutically active compounds
IL87674A (en) 1987-09-08 1993-08-18 Lilly Co Eli Azabicycloalkyl esters and amides of heterocyclic acids, their preparation and pharmaceutical compositions containing them
CA1317940C (en) 1987-09-25 1993-05-18 Georges H. P. Van Daele Substituted n-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
ZA889493B (en) 1987-12-24 1989-09-27 Duphar Int Res Method of preparing optically active cyanohydrin derivatives and their conversion products,and optically active compounds to be obtained in this manner
US4859683A (en) * 1988-02-04 1989-08-22 Rorer Pharmaceutical Corporation Certain benzoxepins and their pharmaceutical compositions and methods
JP2643274B2 (ja) 1988-04-08 1997-08-20 三菱化学株式会社 イミダゾ〔１，２−ａ〕ピリジン誘導体
EP0387431A1 (de) 1989-03-14 1990-09-19 Beecham Group Plc Imidazolderivate, Verfahren zu deren Herstellung und deren Anwendung als pharmazeutische Mittel
WO1991000858A1 (en) 1989-07-07 1991-01-24 Schering Corporation Pharmaceutically active compounds
GB9009389D0 (en) * 1990-04-26 1990-06-20 Smith Kline French Lab Treatment
GB9103862D0 (en) 1991-02-25 1991-04-10 Glaxo Group Ltd Chemical compounds
US5196547A (en) * 1991-03-07 1993-03-23 G. D. Searle & Co. Meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof
US5219850A (en) * 1991-03-07 1993-06-15 G. D. Searle & Co. Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof
US5137893A (en) * 1991-03-07 1992-08-11 G. D. Searle & Co. Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof
US5260303A (en) 1991-03-07 1993-11-09 G. D. Searle & Co. Imidazopyridines as serotonergic 5-HT3 antagonists
EP0596933A1 (de) 1991-08-03 1994-05-18 Smithkline Beecham Plc 5-HT4 Rezeptor - Antigonisten
WO1993003725A1 (en) 1991-08-20 1993-03-04 Smithkline Beecham Plc 5-ht4 receptor antagonists
SG49153A1 (en) 1991-09-12 1998-05-18 Smithkline Beecham Plc 5-HT4 receptor antagonists
EP0603220A1 (de) 1991-09-12 1994-06-29 Smithkline Beecham Plc Azabicyclische Verbindungen als 5-HT4 Rezeptor Antagonisten
GB9121835D0 (en) 1991-10-15 1991-11-27 Smithkline Beecham Plc Pharmaceuticals
US20020128172A1 (en) * 1991-12-21 2002-09-12 Smithkline Beecham Plc Use of 5-HT4 modulators for the manufacture of a medicament for the treatment of the bladder diseases
US5998409A (en) * 1992-03-12 1999-12-07 Smithkline Beecham Plc Condensed indole derivatives as 5HT4 -receptor antagonists
US5852014A (en) * 1992-03-12 1998-12-22 Smithkline Beecham P.L.C. Condensed indole derivatives as 5HT4 -receptor antagonists
WO1993018036A1 (en) 1992-03-12 1993-09-16 Smithkline Beecham Plc Condensed indole derivatives as 5ht4-receptor antagonists
GB9219163D0 (en) 1992-09-10 1992-10-28 Smithkline Beecham Plc Pharmaceuticals
MX9305947A (es) 1992-09-29 1994-06-30 Smithkline Beecham Plc Compuestos antagonistas del receptor 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
GB9221468D0 (en) 1992-10-13 1992-11-25 Smithkline Beecham Plc Pharmaceuticals
EP0664805A1 (de) 1992-10-13 1995-08-02 Smithkline Beecham Plc Heterozyklische karbonsäure-estern oder amide verwendbar als 5-ht4 rezeptor antagonisten
MX9306311A (es) 1992-10-13 1994-04-29 Smithkline Beecham Plc Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
WO1994008965A1 (en) 1992-10-16 1994-04-28 Smithkline Beecham Plc N-alkylpiperidinyl-4-methyl carboxylic esters/amides of condensed ring systems as 5-ht4 receptor antagonists
EP0667867A1 (de) 1992-11-05 1995-08-23 Smithkline Beecham Plc Piperidinderivate als 5-ht4 rezeptor antagonisten
US5472866A (en) * 1992-12-24 1995-12-05 Synaptic Pharmaceutical Corporation DNA encoding 5-HT4A serotonin receptors
GB9301660D0 (en) 1993-01-28 1993-03-17 Smithkline Beecham Plc Pharmaceuticals
US6127379A (en) * 1993-02-01 2000-10-03 Smithkline Beecham P.L.C. Benzopyran, benzothiopyran and benzofuran derivatives as 5-HT4 antagonists
GB9310582D0 (en) * 1993-05-22 1993-07-07 Smithkline Beecham Plc Pharmaceuticals
TW282460B (de) 1993-12-28 1996-08-01 Yamanouchi Pharma Co Ltd
WO1995026953A1 (en) 1994-03-30 1995-10-12 Yoshitomi Pharmaceutical Industries, Ltd. Benzoic acid compound and use thereof as medicine
JPH07302236A (ja) * 1994-05-06 1995-11-14 Hitachi Ltd 情報処理システムおよびその方法並びに情報処理システムにおけるサービス提供方法
AU6856094A (en) 1994-06-01 1995-12-21 Yamanouchi Pharmaceutical Co., Ltd. Oxadiazole derivative and medicinal composition thereof
WO1996005166A1 (en) 1994-08-11 1996-02-22 Yamanouchi Pharmaceutical Co., Ltd. Substituted amine derivative and medicinal composition containing the same
US6100339A (en) * 1994-11-21 2000-08-08 Asahi Kasei Kogyo Kabushiki Kaisha Curable resin and resin composition comprising the same
ES2103675B1 (es) 1995-01-10 1998-07-01 Almirall Lab Nuevas piperidinas sustituidas.
IT1275903B1 (it) * 1995-03-14 1997-10-24 Boehringer Ingelheim Italia Esteri e ammidi della 1,4-piperidina disostituita
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
JPH0967347A (ja) 1995-08-30 1997-03-11 Dainippon Pharmaceut Co Ltd 環状アミン誘導体及びそれを含有する医薬組成物
ES2135934T3 (es) 1995-11-09 1999-11-01 Sanofi Synthelabo Compuesto eventualmente bajo la forma de isomero optico puro o de mezcla de tales isomeros.
AU703203B2 (en) 1996-01-30 1999-03-18 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
ES2208870T3 (es) * 1996-02-15 2004-06-16 Janssen Pharmaceutica N.V. Uso de antagonistas del receptor 5ht4 para resolver los efectos gastrointestinales de los inhibidores de la reabsorcion de serotonina.
EP0944388A4 (de) 1996-04-03 2001-08-16 Merck & Co Inc Hemmern von farnesyl protein transferase
JP3911297B2 (ja) 1996-08-16 2007-05-09 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Ｎ―［（１―ｎブチル―４―ピペリジル）メチル］―３，４―ジヒドロ―２Ｈ―［１，３］オキサジノ［３，２―ａ］インドール―１０―カルボキシアミドおよび塩ならびに製造における中間体
FR2752736B1 (fr) 1996-08-30 1998-10-23 Chu Rouen Utilisation d'antagonistes 5-ht4 dans la regulation de la secretion de corticosteroides
GB9618967D0 (en) 1996-09-11 1996-10-23 Smithkline Beecham Plc Pharmaceuticals
JPH10203987A (ja) 1997-01-28 1998-08-04 Dainippon Pharmaceut Co Ltd （ｒ）−１−エチル−４−メチルヘキサヒドロ−１ｈ−１，４−ジアゼピン誘導体を有効成分とするモルヒネ様薬剤誘発嘔吐抑制剤
FR2762316B1 (fr) * 1997-04-18 1999-12-17 Sanofi Synthelabo Derives de 5-aryl-3-(8-azabicyclo[3.2.1] octan-3-yl)-1,3,4- oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
BR9909277A (pt) 1998-03-31 2001-10-16 Acadia Pharm Inc Compostos com atividade em receptores muscarìnicos
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US20020091271A1 (en) * 1998-07-16 2002-07-11 Smithkline Beecham Plc Process for the preparation of an indole derivative
GB9815481D0 (en) 1998-07-16 1998-09-16 Smithkline Beecham Plc Pharmaceuticals
GB9815483D0 (en) 1998-07-16 1998-09-16 Smithkline Beecham Plc Pharmaceuticals
JP4032566B2 (ja) 1999-06-21 2008-01-16 東レ株式会社 発光素子
CN1263698C (zh) * 1999-08-27 2006-07-12 北京新立基真空玻璃技术有限公司 真空玻璃的制造方法及其装置
CA2418904A1 (en) * 2000-08-07 2002-02-14 Laboratoire Glaxosmithkline S.A.S. Use of 5ht4 receptor antagonists in the manufacture of a medicament for the prophylaxis or treatment of atrial fibrillation
NZ535261A (en) * 2000-08-08 2004-12-24 Smithkline Beecham P A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide
JP2004505920A (ja) 2000-08-08 2004-02-26 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー 縮合インドール化合物を含む医薬組成物
US6624162B2 (en) * 2001-10-22 2003-09-23 Pfizer Inc. Imidazopyridine compounds as 5-HT4 receptor modulators
WO2003035649A1 (en) * 2001-10-22 2003-05-01 Pfizer Japan Inc. Imidazopyridine compounds as 5-ht4 receptor modulators
MXPA03000145A (es) * 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
PT1476136E (pt) 2002-02-14 2006-10-31 Glaxo Group Ltd Composicao farmaceutica compreendendo n-((1-n-butil-4-piperidinil)metil)-3,4-di-hidro-2h-(1,3) oxazino (3,2-a) indole-10-carboxamida ou sal e processo de a obter compreendendo granulacao a seco.
DOP2003000703A (es) * 2002-09-20 2004-03-31 Pfizer Compuestos de imidazopiradina como agonistas del receptor 5-ht4
US20070065801A1 (en) 2003-05-21 2007-03-22 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (seotonin) receptor 4 (5-ht4)
UA86204C2 (uk) 2003-09-03 2009-04-10 Пфайзер Инк. Сполуки бензімідазолону, які мають 5-нт4 рецепторну агоністичну активність
JP4740152B2 (ja) 2003-12-23 2011-08-03 セロドス アクスイェ セルスカブ 末梢性５−ｈｔ受容体の修飾因子
RU2374244C2 (ru) 2004-01-07 2009-11-27 Арикс Терапьютикс Стереоизомерные соединения и способы лечения желудочно-кишечных расстройств и расстройств центральной нервной системы
US7843010B2 (en) * 2004-09-30 2010-11-30 Sharp Kabushiki Kaisha Crystalline semiconductor film and method for manufacturing the same
WO2007007072A1 (en) 2005-07-07 2007-01-18 Bio-Medisinsk Innovasjon As 5-htx modulators
CA2615611C (en) 2005-07-22 2011-09-27 Pfizer Inc. Indazole derivatives
WO2007149929A1 (en) 2006-06-23 2007-12-27 Aryx Therapeutics, Inc. Piperidine derivatives for the treatment of gastrointestinal and cns disorders
JO2653B1 (en) 2006-10-24 2012-06-17 شركة جانسين فارماسوتيكا ان. في Tetrahydroflavin 1-carboxylic acid substituted with pyridine or pyrazine inhibit MTB

Also Published As

Publication number Publication date
CA2485600A1 (en) 2003-11-27
GB0211230D0 (en) 2002-06-26
AU2003227949A1 (en) 2003-12-02
US20090169545A1 (en) 2009-07-02
US8829028B2 (en) 2014-09-09
AU2009200050A1 (en) 2009-02-05
AU2009200050B2 (en) 2010-11-11
HK1072012A1 (en) 2005-08-12
CA2485600C (en) 2010-04-20
DK1503764T3 (da) 2010-05-10
EP1503764A1 (de) 2005-02-09
AU2003227949B2 (en) 2008-12-11
WO2003097065A1 (en) 2003-11-27
US20060094715A1 (en) 2006-05-04
ES2339234T3 (es) 2010-05-18
EP1503764B1 (de) 2010-01-06
DE60330857D1 (de) 2010-02-25

Similar Documents

Publication Publication Date Title
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
WO2005107726A3 (en) Method for the treatment of back pain
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
ATE464303T1 (de) Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
TNSN07376A1 (en) Npy antagonists, preparation and use
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
TW200633980A (en) Pyridones useful as inhibitors of kinases
ATE451376T1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
TW200510416A (en) P38 inhibitors and methods of use thereof
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
MXPA04001187A (es) Receptores de interleucina-1 en el tratamiento de enfermedades.
MX2007002311A (es) Antagonistas del receptor de endotelina a(eta) en combinacion con inhibidores de fosfodiesterasa 5 (pdes) y usos de los mismos.
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
WO2006015775A3 (en) Egfr kinase inhibitor combinations for treating respiratory and gastrointestinal disorders
DE602004012578D1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
NO20052272L (no) CCR1-antagonister for behandling av blant annet demylinerene inflamasjonssykdom
ATE465735T1 (de) Verwendung einer kombination von morphin und mindestens einem opiatantagonisten zur behandlung von opiatabhängigkeit und zur verhinderung des nicht-oralen opiatmissbrauchs bei opiatsüchtigen
DE602006017574D1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
ATE454153T1 (de) 5-ht4 antagonisten zur behandlung von herzversagen
NO20071466L (no) 3-substituerte-5- og 6-aminoalkyl indol-2-karboksylsyreamider og relaterte analoger som inhibitorer av kaseinkinase IE

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1503764

Country of ref document: EP